Utilizza questo identificativo per citare o creare un link a questo documento:
|Titolo:||Growth hormone and early treatment.|
|Autori interni:||ANTONIAZZI, Franco|
|Data di pubblicazione:||2015|
|Abstract:||Growth hormone (GH) treatment is approved by the US Food and Drug Administration (FDA) not only for GH deficiency (GHD) but also for other childhood growth disorders with growth failure and/or short stature. GHD is the most frequent endocrine disorder presenting with short stature in childhood. During neonatal period, metabolic effects due to congenital GHD require a prompt replacement therapy to avoid possible life-threatening complications. In childhood and adolescence, growth impairment is the most evident effect of GHD and early treatment has the aim of restore normal growth and to reach normal adult height. We reassume in this review the conditions causing GHD and the diagnostic challenge to reach an early diagnosis, and an early treatment, necessary to obtain the best results. Finally, we summarize results obtained in clinical studies about paediatric patients with GHD treated at an early age, in which a marked early catch-up growth and a normalization of adult height were obtained|
|Appare nelle tipologie:||01.01 Articolo in Rivista|
- PubMed Central loading...
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.